¹⁸F-labeled anti-human CD20 cys-diabody for same-day immunoPET in a model of aggressive B cell lymphoma in human CD20 transgenic mice.

ABSTRACT:

Purpose

Metabolic imaging using [¹⁸F]FDG is the current standard for clinical PET; however, some malignancies (e.g., indolent lymphomas) show low avidity for FDG. The majority of B cell lymphomas express CD20, making it a valuable target both for antibody-based therapy and imaging. We previously developed PET tracers based on the humanised anti-CD20 antibody obinutuzumab (GA101). Preclinical studies showed that the smallest bivalent fragment, the cys-diabody (GAcDb, 54.5 kDa) with a peak uptake at 1-2 h post-injection and a biological half-life of 2-5 h, is compatible with short-lived positron emitters such as fluorine-18 (¹⁸F, t_1/2 110 min), enabling same-day imaging.

Methods

GAcDb was radiolabeled using amine-reactive N-succinimidyl 4-[

SUBMITTER: Zettlitz KA 

PROVIDER: S-EPMC6580847 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature